About Mesh Bio
Mesh Bio is a company based in Singapore (Singapore) founded in 2018 by Andrew Wu, Melvin Heng, and Arsen Batagov. Mesh Bio has raised $6.5 million across 2 funding rounds from investors including Enterprise Singapore, East Ventures and TeKnowledge. Mesh Bio offers products and services including DARA and HealthVector Diabetes Solutions. Mesh Bio operates in a competitive market with competitors including Verily, Wellframe, Memora Health, MD Revolution and Medlinker, among others.
- Headquarter Singapore, Singapore
- Founders Andrew Wu, Melvin Heng, Arsen Batagov
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mesh Bio Pte. Ltd.
-
Annual Revenue
$262.62 K (USD)89as on Dec 31, 2022
-
Net Profit
-$1.08 M (USD)-50as on Dec 31, 2022
-
EBITDA
-$1.08 M (USD)-50as on Dec 31, 2022
-
Total Equity Funding
$6.5 M (USD)
in 2 rounds
-
Latest Funding Round
$4.7 M (USD), Series A
Oct 12, 2023
-
Investors
Enterprise Singapore
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mesh Bio
Mesh Bio offers a comprehensive portfolio of products and services, including DARA and HealthVector Diabetes Solutions.
Platform for interpreting health screening results and guiding interventions.
AI tool for predicting and managing diabetes risks in patients.
Funding Insights of Mesh Bio
Mesh Bio has successfully raised a total of $6.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.7 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mesh Bio
Mesh Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Enterprise Singapore, East Ventures and TeKnowledge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in Southeast Asian startups and publishing reports on technology and sustainability.
|
Locked | Locked | Locked | |
|
Government-backed fund investing in tech startups
|
Locked | Locked | Locked | |
|
Venture capital is provided to early-stage technology startups.
|
Locked | Locked | Locked |
Investor details for Mesh Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mesh Bio
Investment portfolio details for Mesh Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mesh Bio
Detailed financials for Mesh Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mesh Bio Comparisons
Peer comparison for Mesh Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mesh Bio
Mesh Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Verily, Wellframe, Memora Health, MD Revolution and Medlinker, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based solutions for health management are provided.
|
|
| Locked | Locked | Locked |
Mobile and AI-based platform offering support to providers for better patient engagement
|
|
| Locked | Locked | Locked |
Mobile messaging platform is utilized for chronic disease management.
|
|
| Locked | Locked | Locked |
Predictive analytics SaaS platform for patient engagement is provided.
|
|
| Locked | Locked | Locked |
Social networking for healthcare professionals is facilitated by Medlinker.
|
|
| Locked | Locked | Locked |
Cloud-based platform for long-term care coordination is provided.
|
Detailed competitors of Mesh Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mesh Bio
Complete news archive for Mesh Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mesh Bio
Mesh Bio was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Mesh Bio is headquartered in Singapore, Singapore.
Andrew Wu is the current CEO of Mesh Bio. They have also founded this company.
Mesh Bio is a funded company, having raised a total of $6.5M across 2 funding rounds to date.
Annual revenue of Mesh Bio is $262.62K as on Dec 31, 2022.
Mesh Bio was founded in 2018 in Singapore and operates in the health technology sector. Software is developed for chronic disease management, where clinical data is analyzed through predictive analytics to generate actionable insights. These insights are used by patients to address health, lifestyle, and disease risks. Clinical decision support is also supplied to healthcare professionals for informed practices.
Mesh Bio's top competitors include Verily, Memora Health and Wellframe.
Mesh Bio offers DARA and HealthVector Diabetes Solutions.
Mesh Bio has 7 investors. Key investors include Enterprise Singapore, East Ventures, TeKnowledge, SEEDS Capital, and Elev8.vc.